Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

13    Bristol-Myers Squibb    $10.9B     up 11.2%
Global revenue: $21.2B (11th); up 8.7%

R&D spend: $3.6B (11th), up 5.9%; 17.0% of rev.

Top brands: Plavix ($6.8B), Abilify ($5.2B), Avapro ($952M), Sustiva ($940M)

Planned launches: Eliquis (SPAF); brivanib (onc.); necitumumab (onc.)

Promotional spend: $906M (7th); 8.3% of rev.

Patent expirations: Plavix (2012), Avapro (2012), Abilify (2015)

Bernstein analyst Tim Anderson forsees eight years of flattish growth for BMS. Among the reasons: losing exclusivity of blockbuster drug Plavix this month and pushback from the FDA, which wants more information about its diabetes contender dapagliflozin, which, if approved, would join a crowded market. On tap is the blood thinner Eliquis—the FDA delayed review for this drug, as well, by three months. The firm's recent strategy has included buying biotech Inhibitex in February 2012 and Amira in September 2011, as well as jettisoning non-pharmaceutical brands. Anderson says the sell-offs have made BMS the most “pure play” pharmaceutical company he covers in the US and Europe.

Back to first page

Page 13 of 21
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters